Poxel Stock

POXEL

FR0012432516

Biotechnology & Medical Research

Real-time Euronext Paris 13:44:41 08/09/2026 +04			5-day change	1st Jan Change
0.1880 ^EUR	-1.98%		-4.95%	-19.66%

09-04	Laure-Hélène Mercier takes over as chair of Poxel's board
09-04	Poxel Names New Board Chair	MT

Analysts' recommendations : Poxel

28/03/23

Poxel: Degroof Petercam reduces its target

More recommendations

News in other languages : Poxel

09-04	Bourse : super contrat pour Alstom, super plan social pour Volkswagen, super chute pour Lululemon
09-04	A Wall Street, les mots ont encore du poids
09-04	Laure-Hélène Mercier prend la présidence du conseil de Poxel
09-03	Laure-Hélène Mercier cooptée à la Présidence du Conseil d’administration de Poxel
07-31	Poxel publie ses revenus trimestriels et reporte la publication des comptes 2025

More news

Managers and Directors : Poxel

Manager	Title	Age	Since
Yves Decadt CEO	Chief Executive Officer	59	10/06/2026
Fanny Bosa DFI	Director of Finance/CFO	-	01/12/2022
Tejdeep Bawa PRN	Corporate Officer/Principal	-	01/05/2023

Director	Title	Age	Since
Amit Kohli BRD	Director/Board Member	-	31/07/2025
Alexandre Bragadir BRD	Director/Board Member	-	31/07/2025
Yves Decadt BRD	Director/Board Member	59	31/10/2025

More insiders

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/09/26	€0.1880	-1.98%	148,220
07/09/26	€0.1918	-0.42%	113,727
04/09/26	€0.1926	-2.13%	372,280
03/09/26	€0.1968	-0.10%	204,501
02/09/26	€0.1970	-0.40%	425,154

Real-time Euronext Paris

More quotes

Analysis / Opinion

MarketScreener roundup: Poxel, Haffner, Europlasma, the Return of the Living Dead

December 04, 2025 at 07:27 pm

More analyses

Market Cap	12.57M 14.62M 11.83M 10.79M 20.19M 1.38B 20.25M 140M 54.2M 708M 54.9M 53.7M 2.26B	P/E 2023	-0.52x	P/E 2024	-0.36x
Enterprise Value	79.65M 92.62M 74.92M 68.39M 128M 8.76B 128M 888M 343M 4.49B 348M 340M 14.29B	EV / Sales 2023	33.3x	EV / Sales 2024	11.2x
Free-Float	94.27%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	POXEL	Real-time
CBOE	POXELp	Real-time
OTC Markets	PXXLF	Delayed
Deutsche Boerse AG	7PO	Delayed
CBOE	0RA2	Real-time
London S.E.	0RA2	Delayed
Börse Stuttgart	7PO	Delayed
Boerse Muenchen	7PO	Real-time

09-04	Laure-Hélène Mercier takes over as chair of Poxel's board
09-04	Poxel Names New Board Chair	MT
09-03	Poxel Sa Announces Board Changes, Effective September 3, 2026	CI
07-31	Poxel S.A. Reports Sales Results for the Quarter Ended 30 June 2026	CI
07-31	Poxel SA Delays Earnings Results Release for the 2025 Financial Statements	CI
06-15	MarketScreener Corporate Earnings Calendar: Week of June 15 to 19, 2026
06-15	Weekly Earnings Calendar: Accenture and Orsted Stand Out
06-11	Yves Decadt appointed CEO of Poxel
06-11	Biopharmaceutical Company Poxel Names New CEO	MT
06-10	Poxel S.A. Announces CEO Changes	CI
05-20	Poxel reports sharp increase in quarterly revenue
05-20	Poxel S.A. Reports Consolidated Revenue for the First Quarter Ended March 31, 2026	CI
03-31	SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease	MT

09-03	Laure-Hélène Mercier Co-Opted as Chair of the Board of Directors of Poxel	BU
07-30	Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements	BU
06-10	Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships	BU
05-20	Poxel : Quarterly financial reporting / First quarter financial report	PU
05-20	Poxel Reports First Quarter 2026 Revenue and Provides a Business Update	BU

1 day	-1.98%
1 week	-4.95%
Current month	-6.47%
1 month	-6.93%
3 months	-16.63%
6 months	-24.19%
Current year	-19.66%

Poxel Stock

Stocks

POXEL

FR0012432516

Biotechnology & Medical Research

Valuation : Poxel

Chart: Poxel

Latest news : Poxel

Analysts' recommendations : Poxel

Press Releases : Poxel

News in other languages : Poxel

Quotes and Performance

Price Extremes

Managers and Directors : Poxel

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysis / Opinion

1 week	0.18	0.2
1 month	0.18	0.25
Current year	0.18	0.48
1 year	0.18	0.48
3 years	0.12	0.95
5 years	0.12	6.84
10 years	0.12	13.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/02/22	Thomas Kuhn	Exercice	Founder	67,000	0.2334%
04/02/22	Thomas Kuhn	Exercice	Founder	6,666	0.0232%
30/01/21	Thomas Kuhn	Free	Founder	25,263	0.0888%

	2023	2024
Net sales	1.98M 2.3M 1.86M 1.7M 3.18M 218M 3.19M 22.09M 8.54M 112M 8.65M 8.46M 355M	6.64M 7.72M 6.24M 5.7M 10.66M 730M 10.69M 74M 28.61M 374M 28.98M 28.34M 1.19B
Net income	-35.09M -40.8M -33M -30.13M -56.35M -3.86B -56.53M -391M -151M -1.98B -153M -150M -6.29B	-18.3M -21.28M -17.22M -15.72M -29.39M -2.01B -29.49M -204M -78.91M -1.03B -79.93M -78.19M -3.28B
Net Debt	46.42M 53.98M 43.66M 39.86M 74.54M 5.11B 74.78M 518M 200M 2.61B 203M 198M 8.33B	67.08M 78M 63.09M 57.59M 108M 7.38B 108M 748M 289M 3.78B 293M 287M 12.03B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POXEL	-1.98%	-4.95%	-37.75%	-66.61%	11.98M
WUXI APPTEC CO., LTD.	-0.38%	-0.99%	+42.69%	+100.85%	67.82B
ARGENX SE	-0.62%	-2.51%	+33.25%	+78.25%	63.22B
INSMED INCORPORATED	-0.31%	+3.67%	-12.96%	+374.95%	27.58B
BIONTECH SE	+0.86%	+2.12%	-7.74%	-13.34%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	+1.69%	-0.36%	+26.48%	+15.46%	25.38B
GENMAB A/S	+1.49%	+1.12%	+24.84%	-17.61%	19.89B
PHARMAESSENTIA CORPORATION	+1.15%	-5.02%	+219.82%	+379.02%	17.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.49%	-0.37%	-7.31%	+524.84%	14.95B
EXELIXIS, INC.	-0.20%	+8.00%	+55.78%	+167.98%	14.62B
Average	+0.12%	+1.05%	+33.71%	+154.38%	27.69B
Weighted average by Cap.	+0.11%	+0.90%	+36.60%	+139.82%